Stock events for Viridian Therapeutics, Inc. (VRDN)
Several events have impacted Viridian Therapeutics, Inc.'s stock price over the past six months. In September 2025, enrollment was completed in VRDN-003's Phase 3 REVEAL-1 and REVEAL-2 clinical trials, and VRDN-006 showed IgG reductions. In October 2025, the BLA was submitted to the FDA for veligrotug, and financing transactions were completed. In November 2025, Q3 financial results were reported, with EPS exceeding expectations. In December 2025, non-qualified stock options were approved as inducement grants. In January 2026, an MAA was submitted for veligrotug to the EMA, and the IND application for VRDN-008 was cleared. In February 2026, Q4 and full-year 2025 financial results were reported, with Q4 EPS and revenue missing consensus estimates. RBC Capital lowered its price target on VRDN, while maintaining an "Outperform" rating. Topline data readouts for VRDN-003's REVEAL-1 and REVEAL-2 studies are anticipated in Q1 and Q2 2026, respectively, and the PDUFA target date for veligrotug is June 30, 2026.
Demand Seasonality affecting Viridian Therapeutics, Inc.’s stock price
There is no explicit information available regarding demand seasonality for Viridian Therapeutics, Inc.'s products or services. Demand for its products is typically driven by disease prevalence, diagnosis rates, and treatment efficacy rather than seasonal fluctuations.
Overview of Viridian Therapeutics, Inc.’s business
Viridian Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious and rare diseases, particularly thyroid eye disease (TED). Its major product candidates include Veligrotug, a humanized monoclonal antibody targeting IGF-1R, VRDN-003, a next-generation IGF-1R antibody for subcutaneous administration and VRDN-006 and VRDN-008, a portfolio of neonatal Fc receptor (FcRn) inhibitors being developed for multiple autoimmune diseases.
VRDN’s Geographic footprint
Viridian Therapeutics, Inc. is headquartered in Waltham, Massachusetts, United States. The company conducts global Phase 3 clinical trials and has submitted a Marketing Authorization Application (MAA) for veligrotug to the European Medicines Agency (EMA), indicating an international reach.
VRDN Corporate Image Assessment
Viridian Therapeutics, Inc. generally holds a positive brand reputation, particularly among analysts, with a consensus rating of "Buy". This positive outlook is driven by the company's promising pipeline, strong clinical execution, and the potential of its lead product candidates to address unmet needs in thyroid eye disease. There have been no specific events in the past year that have negatively impacted Viridian Therapeutics, Inc.'s reputation, beyond the typical risks associated with clinical-stage biopharmaceutical companies.
Ownership
Viridian Therapeutics, Inc. has significant institutional ownership, with approximately 112.94% of the company's stock held by institutional shareholders, 32.59% by Viridian Therapeutics insiders, and 0.00% by retail investors. Major institutional owners include FMR LLC, BlackRock Inc., The Vanguard Group, Inc., Bellevue Asset Management AG, Logos Global Master Fund LP, Commodore Capital Master LP, Fairmount Healthcare Fund II L.P., Fairmount Funds Management LLC, VR Management, LLC, State Street Global Advisors, Inc., T. Rowe Price Group, Inc., Perceptive Advisors Llc and Deep Track Capital, LP.
